Methylphenidate extended-release chewable tablets - Pfizer

Drug Profile

Methylphenidate extended-release chewable tablets - Pfizer

Alternative Names: NWP-09; QuilliChew ER

Latest Information Update: 14 Jan 2016

Price : $50

At a glance

  • Originator NextWave Pharmaceuticals
  • Developer Pfizer; Tris Pharma
  • Class Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Attention-deficit hyperactivity disorder

Most Recent Events

  • 07 Dec 2015 Registered for Attention-deficit hyperactivity disorder (In children)- First global approval in USA (PO)
  • 07 Dec 2015 Adverse events data from the REFOCUS phase III trial in Attention-deficit hyperactivity disorder released by Pfizer
  • 28 Nov 2012 NextWave Pharmaceuticals has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top